NeoImmuneTech Statistics

Total Valuation

NeoImmuneTech has a market cap or net worth of KRW 21.08 billion. The enterprise value is -2.99 billion.

Market Cap	21.08B
Enterprise Value	-2.99B

Important Dates

The next estimated earnings date is Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

NeoImmuneTech has 19.77 million shares outstanding. The number of shares has decreased by -0.22% in one year.

Current Share Class	n/a
Shares Outstanding	19.77M
Shares Change (YoY)	-0.22%
Shares Change (QoQ)	-1.05%
Owned by Insiders (%)	4.78%
Owned by Institutions (%)	4.79%
Float	14.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	123.71
PB Ratio	0.51
P/TBV Ratio	0.60
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.07
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.07

Financial Position

The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.26.

Current Ratio	1.89
Quick Ratio	1.68
Debt / Equity	0.26
Debt / EBITDA	n/a
Debt / FCF	-0.25
Interest Coverage	-56.43

Financial Efficiency

Return on equity (ROE) is -70.17% and return on invested capital (ROIC) is -39.04%.

Return on Equity (ROE)	-70.17%
Return on Assets (ROA)	-32.84%
Return on Invested Capital (ROIC)	-39.04%
Return on Capital Employed (ROCE)	-91.78%
Revenue Per Employee	2.08M
Profits Per Employee	-498.57M
Employee Count	82
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.45% in the last 52 weeks. The beta is 0.82, so NeoImmuneTech's price volatility has been lower than the market average.

Beta (5Y)	0.82
52-Week Price Change	-45.45%
50-Day Moving Average	1,090.38
200-Day Moving Average	1,262.35
Relative Strength Index (RSI)	45.44
Average Volume (20 Days)	702,300

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NeoImmuneTech had revenue of KRW 170.38 million and -40.88 billion in losses. Loss per share was -414.60.

Revenue	170.38M
Gross Profit	170.38M
Operating Income	-40.97B
Pretax Income	-40.87B
Net Income	-40.88B
EBITDA	-37.01B
EBIT	-40.97B
Loss Per Share	-414.60

Full Income Statement

Balance Sheet

The company has 34.84 billion in cash and 10.77 billion in debt, giving a net cash position of 24.06 billion or 1,217.00 per share.

Cash & Cash Equivalents	34.84B
Total Debt	10.77B
Net Cash	24.06B
Net Cash Per Share	1,217.00
Equity (Book Value)	41.66B
Book Value Per Share	425.86
Working Capital	18.55B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -42.10 billion and capital expenditures -1.67 billion, giving a free cash flow of -43.77 billion.

Operating Cash Flow	-42.10B
Capital Expenditures	-1.67B
Free Cash Flow	-43.77B
FCF Per Share	-2,213.48

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-24,047.07%
Pretax Margin	-23,987.05%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NeoImmuneTech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.22%
Shareholder Yield	0.22%
Earnings Yield	-193.96%
FCF Yield	-207.64%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NeoImmuneTech has an Altman Z-Score of -7.91. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.91
Piotroski F-Score	n/a